SRPT Share Price Performance
US$16.78
-1.16 (-6.47%)
22.5% undervalued intrinsic discount
US$21.65
Fair Value
Price US$16.78
AnalystConsensusTarget US$21.65
AnalystLowTarget US$7.02
AnalystHighTarget US$37.38
Fair ValueUS$21.65
Share Pricen/a
Sarepta Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 88 Fair Values set on narratives written by author
SRPT Community Narratives
AN
Fair Value
·Fair Value US$21.65 22.5% undervalued intrinsic discount
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
3users have liked this narrative
1users have commented on this narrative
40users have followed this narrative
AN
Fair Value
·Fair Value US$7.02 139.0% overvalued intrinsic discount
Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$37.38 55.1% undervalued intrinsic discount
Rising Genetic Testing And Precision Medicine Will Unlock New Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement
Sarepta’s gene therapy rollout faces a tough mix of infusion delays and fresh safety scrutiny after a patient death, which could slow treatment starts and strain trust among doctors and families. With heavy reliance on a few key programs and limited treatment-site capacity, the company’s next phase depends on fixing logistics and navigating regulators before growth can restart.Read more
AN
US$7.02
139.0% overvalued intrinsic discount
Fair Value
Revenue
-36.12% p.a.
Profit Margin
18.92%
Future PE
10.58x
Price in 2029
US$8.81
Rising Genetic Testing And Precision Medicine Will Unlock New Markets
Sarepta Therapeutics could reach more patients as genetic testing becomes more common and insurers grow more willing to cover its gene therapy, while a broader network of treatment sites helps more people get treated. But the story hinges on one main product, and safety scrutiny, pricing pressure, and high development costs could quickly change the outlook.Read more
AN
US$37.38
55.1% undervalued intrinsic discount
Fair Value
Revenue
-9.32% p.a.
Profit Margin
14.29%
Future PE
26.17x
Price in 2029
US$47.08
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Key Takeaways Addressing operational delays and administrative complexities in gene therapy could enhance revenue by quickly converting demand into treated patients. Expanding into LGMD and siRNA platforms diversifies revenue, potentially boosting earnings and financial stability.Read more
AN
US$21.65
22.5% undervalued intrinsic discount
Fair Value
Profit Margin
6.09%
Future PE
39.8x
Price in 2029
US$27.13
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
SRPT: 2027 Duchenne Decision Will Pressure Shares Despite Conflicted Street Views
Fair Value: US$7.02 139.0% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SRPT: 2026 Guidance And siRNA Data Readouts Will Drive Upside Potential
Fair Value: US$37.38 55.1% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Fair Value: US$21.65 22.5% undervalued intrinsic discount
40 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
1 likeusers have liked this narrative
Snowflake Analysis
Sarepta Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.29
- -17.30%
- -6.93%
- 55.5%
About SRPT
- Founded
- 1980
- Employees
- 835
- CEO
- WebsiteView website
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
